SurModics — Investor Presentation (September 2011)
32 slides from SurModics's investor presentation, Sep 14, 2011
Slide 1: Investor Presentation
Investor Presentation Maharaj Gary Maharaj, President and CEO © 2011 SurModics, Inc. 1 © 2011 SurModics, Inc. September 2011
Slide 2: Safe Harbor Statement
Safe Harbor Statement Some of the statements made during this meeting may be considered forward-looking statements. The 10-K for fiscal year 2010 identifies certain factors that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements made
Slide 3: SurModics: Company Snapshot
SurModics: Company Snapshot SurModics is a market leader in technology for the development of (1) hydrophilic coatings that enable or improve minimally invasive • NASDAQ: SRDX medical procedures and (2) immunoassay reagents that help to accurately diagnosis the absence or presence of disease. • Head
Slide 4: Where We Are Today
Where We Are Today Refocused on our core businesses • Core businesses have a pedigree of consistently outperforming the market • Commitment to R&D activities provides our Medical Device and IVD businesses with the potential for meaningful, differentiated products Leading market positions aided by di
Slide 5: Strategic Plan Overview
Strategic Plan Overview Define and Focus on the Core Businesses • Tightly define the core businesses and their boundaries in terms of customers, products, and technologies • Drive profitable growth in the core businesses over the near- and medium-term (roughly the next 1-2 years) – Identify and capt
Slide 6: Focus on the Core Business
Focus on the Core Business Complementary Businesses: Detect and Treat Tightly Defined Core Businesses • Generates the majority of the revenue for the business • Leverages existing strategic assets such as people, technology, expertise and customer base • Generates growth for the business with the hi
Slide 7: Pharma – Strategic Alternatives Process
Pharma – Strategic Alternatives Process Announcement • Announced plan in December 2010 to explore strategic alternatives for the Pharmaceuticals business, including a potential sale Rationale • Company intently focused on returning to profitable growth • The Pharmaceuticals business maintains sound,
Slide 8: Business Overview
Business Overview © 2011 SurModics, Inc. 8
Slide 9: Medical Device Business Overview
Medical Device Business Overview Sales Contribution Hydrophilic coatings for catheter-based vascular delivery systems • Market leader in hydrophilic coatings (75% industry market share) • We partner with > 80% out of the top 15 cardio medical device companies globally • Relevant core technologies wi
Slide 10: SurModics Hydrophilic Coatings for Medical Devices
SurModics Hydrophilic Coatings for Medical Devices Deliverability Matters © 2011 SurModics, Inc. 10 Long access paths Challenging therapy sites Brain vessels Coronary arteries Long access paths and tortuous anatomy underscore the need for lubricous coatings to ensure successful delivery of medical d
Slide 11: Market Opportunity – Hydrophilic Coatings
Market Opportunity – Hydrophilic Coatings Hydrophilic Coating Market • SurModics owns 75% of market share within hydrophilic industry in-house uncoated opportunity 51% – Product offering appeals to key customer needs across price, quality, and efficiency variables • Overall hydrophilic coating marke
Slide 12: Competitive Advantages
Competitive Advantages • Strong brand and customer relationships • Technical superiority—lubricity and durability • Operational efficiency—simple, low cost, repeatable manufacturing processes • Strong regulatory track record—FDA master files • Deep intellectual property portfolio • Few competitors i
Slide 13: In Vitro Diagnostics Business Overview
In Vitro Diagnostics Business Overview Sales Contribution Our reagents support more complex Immunoassay reagents that improve the performance of diagnostic test kits • diagnostic tests, such as infectious disease (e.g., HIV) and autoimmune disease (e.g., Lupus) • Improve specificity and accuracy of
Slide 14: Market Overview – In Vitro Diagnostics
Market Overview – In Vitro Diagnostics • SurModics participates primarily in the $400M autoimmune and infectious disease immunoassay market – as a supplier to the manufacturers of diagnostic test kits Small Market Size • The overall IVD market is growing at a modest 5% annually with certain smaller
Slide 15: Strategy Overview
Strategy Overview • Increase use of SurModics’ reagents in customer diagnostic kits – Increase customer base (# of kit manufacturer customers) – Increase “share of kit” (more SRDX components per diagnostic kit) • Develop and launch new immunoassay components that… – Improve test result accuracy – Re
Slide 16: Competitive Advantages
Competitive Advantages • Strong brand and customer relationships • Superior product performance — SRDX stabilization products are considered the “gold standard” in the industry • Extends shelf-life of diagnostic kits (at room temperature) • Custom fills, bulk options, and special labeling options ar
Slide 17: Financial Review
Financial Review Tim Arens, Vice President of Finance and Interim CFO © 2011 SurModics, Inc. 17 © 2011 SurModics, Inc.
Slide 18: Business Model – Q3 FY2011
Business Model – Q3 FY2011 Revenue by Type $18.0M Revenue by Business Unit IVD 19% Royalties and License Fees $7 5M Pharma 28% Medical Device 53% 7.5M 42% Operating Results Product Sales $5.8M 32% • Revenue $18.0M • Operating Margin 19% • Net Margin* 13% R & D $4.6M 26% © 2011 SurModics, Inc. 18 *no
Slide 19: Q3 FY2011 GAAP Results
Q3 FY2011 GAAP Results (000's) Q3 2011 Q2 2011 Change Revenue: $ $ Royalties and License Fees 7,529 7,692 -2% Product Sales 5,839 5,818 0% Research & Development 4,599 3,984 15% 17 967 17 494 3% Total Revenue 17,967 17,494 Cost of Sales 1,704 2,284 -25% Operating Expenses 12,817 13,168 -3% Impairmen
Slide 20: Revenue Performance
Revenue Performance © 2011 SurModics, Inc. 20 * Non-GAAP revenue – excluding Merck and Abbott royalties. See segment reconciliation table on slide 33. Revenue* (in millions) Medical Device IVD Pharma 1Q’10 2Q’10 3Q’10 4Q’10 1Q’11 2Q’11 3Q’11 1Q’09 2Q’09 3Q’09 4Q’09 $0 $2 $4 $6 $8 $10 $12
Slide 21: Medical Device Revenue Performance
Medical Device Revenue Performance © 2011 SurModics, Inc. 21 * Non-GAAP revenue – excluding Merck and Abbott royalties. See segment reconciliation table on slide 33. 1Q’10 2Q’10 3Q’10 4Q’10 1Q’11 2Q’11 3Q’11 1Q’09 2Q’09 3Q’09 4Q’09 $0 $2 $4 $6 $8 $10 $12 Medical Device Device Drug Delivery Hydrophil
Slide 22: Segment Operating Income Performance
Segment Operating Income Performance © 2011 SurModics, Inc. 22 * Non-GAAP operating income (loss) – excluding Merck and Abbott royalties, as well as certain charges. See segment reconciliation table on slide 33. 1Q’10 2Q’10 3Q’10 4Q’10 1Q’11 2Q’11 3Q’11 1Q’09 2Q’09 3Q’09 4Q’09 -$6 -$4 -$2 $0 $2 $4 $
Slide 23: Strong Balance Sheet
Strong Balance Sheet • $63.2 million in cash and investments as of June 30, 2011 • No debt • History of operating cash flow generation Operating Cash Flow © 2011 SurModics, Inc. 23 $0 $20 $40 $60 98 99 00 01 02 03 04 05 06 07 08 09 10 2.1 4.4 7.4 7.8 14.3 17.1 23.2 26.0 35.3 50.7 39.8 31.3 22.0
Slide 24: Investor Relations Contact
Investor Relations Contact For additional inquiries, please contact: Tim Arens 952-500-7056 © 2011 SurModics, Inc. 24
Slide 25: Appendix
Appendix © 2011 SurModics, Inc. 25
Slide 26: Strategic Evolution of SurModics
Strategic Evolution of SurModics 1998: Initial Public Offering April 2003: FDA approval of J&J/Cordis Cypher stent January 2005: Acquired InnoRx and related drug delivery technologies FY2006: Peak of Cypher royalties July 2007: Acquired Brookwood August 2007: Acquired BioFX Laboratories, bolstering
Slide 27: What We Do… Our Core…
What We Do… Our Core… Components for Diagnostic Test Kits (ELISA example) develop manufacture Colorimetric Substrate (detection) Liquid We develop, and sell immunoassay reagents that enable our Protein Stabilization customers’ diagnostic tests to accurately detect the absence or presence of Antibodi
Slide 28: Positioned for Growth
Positioned for Growth SurModics is well positioned within several key growth markets… • Neurovascular $1 0B – 1.0B neurovascular market growing at 9% – $3.1B U.S. ischemic stroke market opportunity • Percutaneous – $3.0B transcatheter aortic valve implantation market opportunity • Peripheral – $1.2B
Slide 29: Q3 FY2011 non-GAAP Results
Q3 FY2011 non-GAAP Results (000's) Q3 2011 Q2 2011 Change Revenue: $ $ Royalties and License Fees 7,480 7,643 -2% Product Sales 5,839 5,818 0% Research & Development 4,599 3,984 15% 17 918 17 445 3% Total Revenue 17,918 17,445 Cost of Sales 1,704 2,284 -25% Operating Expenses 12,817 13,168 -3% Incom
Slide 30: Reconciliation Table Supplemental Non-GAAP Information
Reconciliation Table Supplemental Non-GAAP Information © 2011 SurModics, Inc. 30
Slide 31: Reconciliation Table Supplemental Non-GAAP Information
Reconciliation Table Supplemental Non-GAAP Information © 2011 SurModics, Inc. 31
Slide 32: Historical Segment Results
Historical Segment Results SurModics Consolidated Revenue and Operating Income (Loss) By Segment (in thousands) 2009 2010 2011 1ST QTR 2nd QTR 3rd QTR 4th QTR 1ST QTR 2nd QTR 3rd QTR 4th QTR 1 ST QTR 2ND QTR 3RD QTR Revenue Medical Device 10,457 9,783 10,524 10,794 11,514 10,187 11,683 9,827 9,808 9